The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial
Abstract Background Fibromyalgia is a chronic multidimensional pain disease with no curative treatment currently available. Its management relies on a multimodal approach involving pharmacologic and non-pharmacologic elements. Because a suggested factor in its etiology is a central sensitization phe...
Enregistré dans:
Auteurs principaux: | Zuzana Javorcikova, Michel Dangoisse, Stéphane Nikis, Jean-Paul Lechat, Aline Gillain, Jean-François Fils, Philippe Van der Linden |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMC
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/569b0e77782f454b8c7756c330a5a05b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
DNA Methylation Changes in Fibromyalgia Suggest the Role of the Immune-Inflammatory Response and Central Sensitization
par: Maria Carla Gerra, et autres
Publié: (2021) -
Encefalitis autoinmunes: criterios diagnósticos y pautas terapéuticas
par: Collao-Parra,Juan Pablo, et autres
Publié: (2018) -
Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia
par: Imamura M, et autres
Publié: (2014) -
Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy
par: Anya Ragnhildstveit, et autres
Publié: (2021) -
IMPACT OF FIBROMYALGIA ON DAS-28 SCORE IN RHEUMATOID ARTHRITIS
par: Ata Ur Rehman, et autres
Publié: (2018)